Sorry guys but this is a clasic case of the author comparing...

Sorry guys but this is a clasic case of the author comparing entities based on numbers and metrics without even the vaguest understanding of the stock that they are looking at. The fact that in the opening line they state "the Price to Sales ratio is the most appropriate valuation measure" shows that they don't have any real understanding of MST. Quite simply companies in the R&D state usually have few if any sales so any comparison to other stocks based on sales, revenues or any other such measures is pointless I believe.

While it nice to have standard formulas and metrics to help evaluate and compare stocks its just as important to know which ones to apply in each situation. In my opinion the application of the Sales Ratio metrics here is a waste of time.